BioSpace News Archive

July 14, 2022 20:30 UTC Labcorp, a leading global life sciences company, announced that its Board of Directors has declared a cash dividend of $0.72 per share of common stock.

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its second quarter 2022 financial results after market close on Thursday, August 4, 2022.

Zymo Research Corp., in collaboration with the Institute of Virology, University Medical Center Freiburg, Germany, demonstrated data showing their DNA/RNA Shield™ Inactivating Transport Medium (ITM) completely inactivated recent Monkeypox virus isolates.

Novarad™ announced the publication of the article Augmented Reality Spine Surgery Navigation: Increasing Pedicle Screw Insertion Accuracy for Both Open and Minimally Invasive Spine Surgeries authored by surgeons participating from University of Utah, Georgetown University and University of Washington in the June 2022 issue of SPINE (volume 47, number 12).

CANbridge Pharmaceuticals Inc. (HKEX:1228), announced that the first patient has been dosed in the Phase 2 EMBARK study of CAN108 (maralixibat) in biliary atresia (BA) in China, at Children’s Hospital of Capital Institute of Pediatrics (CIP), in Beijing.

Burning Rock Biotech Limited, a company focused on the application of next generation sequencing technology in the field of precision oncology, announced the resignation of Ms. Yunxia Yang as a director from the board of directors of the Company and a member of the compensation committee of the Board.

PROCEPT® BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the second quarter 2022 after market close on Thursday, August 4, 2022.

Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that the Company has entered into an agreement with Pfizer for the supply of a proprietary high-performance enzyme used to manufacture a critical intermediate for nirmatrelvir, an active pharmaceutical ingredient (API) in PAXLOVID™.

ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, July 29, 2022 to discuss its second quarter 2022 operating results.

Blueprint Medicines Corporation (NASDAQ: BPMC) today published its first Corporate Responsibility Report.